Favipiravir is the only oral anti-viral treatment approved in India for the potential treatment of patients with mild to moderate Covid-19 disease, the company said.
Sun Pharma on August 4 said it has launched Favipiravir 200 mg under brand name FluGuard at a price of Rs 35 per tablet, for the treatment of mild to moderate cases of Covid-19 in India.
Favipiravir is the only oral anti-viral treatment approved in India for the potential treatment of patients with mild to moderate Covid-19 disease, the company said.
At Rs 35 per tablet, Sun Pharma’s Favipiravir version would be the cheapest in the market.
related news
The DCGI has approved Favipiravir versions of half a dozen companies including Glenmark, Cipla, Hetero, Brinton Pharmaceuticals and Jenburkt, despite clinical trial data from Glenmark not being statistically significant.
Dr Reddy’s had earlier signed with the innovator company Fujifilm to sell the drug.
“With over 50,000 Covid-19 cases being reported daily in India, there is an urgent need to provide more treatment options to healthcare professionals,” said Kirti Ganorkar, CEO of India Business of Sun Pharma, said.
“We are launching FluGuard at an economical price to make the drug accessible to more and more patients thereby reducing their financial burden. This is in line with our continuous efforts to support India’s pandemic response,” Ganorkar said.
The company said it will work closely with the government and medical community to ensure availability of FluGuard to patients across the country.
The stocks of FluGuard will be available in the market from this week.
First Published on Aug 4, 2020 04:21 pm
